Novartis AG logo

Novartis (NVS) stock

NVS · Novartis AG · NYSE

Website
Market cap
$287.13B
Shares out
1.91B
52-week range55% up the range
$126.52$170.38

What is the latest news on NVS stock?

NVS fell 0.50% to $150.47 on Nov 20, 2026. No NVS story in the last two days; the most recent is below.

SECago
SEC Form 6-K filed by Novartis AG

6-K - NOVARTIS AG (0001114448) (Filer)

All NVS news
Price$150.47-5.75 (-3.68%)
2026-08-202026-11-20

When does Novartis report earnings?

The latest Novartis earnings release came out on Dec 2, 2024: PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program. Before that, Novartis reported on Mar 8, 2022.

NVS earnings history

Who owns the most NVS stock?

Fisher Asset Management, LLC was the largest reported holder of NVS at the end of Q2 2026, with 15,523,378 shares worth $2.4 billion. Next came Morgan Stanley ($1.4 billion) and Dimensional Fund Advisors LP ($1.3 billion). In all, 1,618 institutions reported $21.3 billion of NVS in their 13F filings.

All NVS fund holders

Financial highlights

Full financials
Revenue, FY2025
$54.53B
Revenue growth
+8.4%
Net income, FY2025
$13.98B
Net margin
25.6%
Free cash flow, FY2025
$17.60B
Cash
$11.44B

For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.

Latest news

25 items

NVS rankings

News · 26 weeks17+100%
2026-05-31: 02026-06-07: 12026-06-14: 02026-06-21: 12026-06-28: 02026-07-05: 02026-07-12: 02026-07-19: 12026-07-26: 02026-08-02: 02026-08-09: 02026-08-16: 02026-08-23: 02026-08-30: 22026-09-06: 62026-09-13: 02026-09-20: 02026-09-27: 02026-10-04: 02026-10-11: 02026-10-18: 02026-10-25: 22026-11-01: 12026-11-08: 22026-11-15: 12026-11-22: 0
2026-05-312026-11-22
Mix1490d
  • SEC Filings7(50%)
  • Analyst4(29%)
  • Other2(14%)
  • Offering1(7%)
Activity · 52 weeks3626 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Our reporting on NVS

Novartis AG (NVS) is a Biotechnology: Pharmaceutical Preparations company listed on NYSE. In the last 30 days Quantisnow tracked 6 wire items for NVS, including 4 SEC filings, 1 analyst rating and 1 press release or news item. The most recent was published Nov 19, 2026.

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

NVS FAQ

9 questions
  • What does Novartis AG do?
    Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic...
  • What is NVS revenue?
    Novartis AG (NVS) reported $54.53B of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 8.4% from the year before.
  • Is NVS profitable?
    Yes. Novartis AG earned $13.98B in net income for fiscal 2025 (ended Dec 31, 2025), a net margin of 25.6%.
  • How much cash and debt does NVS have?
    Novartis AG reported $11.44B in cash and cash equivalents and $28.73B of debt on its most recent balance sheet in SEC filings.
  • Where does NVS stock trade?
    Novartis AG (NVS) is listed on NYSE.
  • What sector and industry is NVS in?
    Novartis AG operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • What are analysts saying about NVS?
    Across the last 8 analyst actions on Novartis AG, there were 4 upgrades and 2 downgrades. The most recent action was from Deutsche Bank: Sell on 2026-10-30. Recent price targets cluster around $180.00.
  • What companies are similar to NVS?
    Notable peers in the same industry include JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), SNY (Sanofi), PFE (Pfizer Inc.), AZN (AstraZeneca PLC). Compare NVS side-by-side with any of them on Quantisnow.
  • How can I track NVS on Quantisnow?
    Quantisnow aggregates Novartis AG's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NVS to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change